Comparing Ibrutinib vs Imbruvica
| Ibrutinib | Imbruvica (ibrutinib) |
|
|---|
| Ibrutinib | Imbruvica (ibrutinib) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ibrutinib is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Prescription only
Imbruvica is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Related suggestions Waldenström Macroglobulinemia
Graft Versus Host Disease
Popular comparisons
|
|||||||
| More about Ibrutinib | More about Imbruvica (ibrutinib) | ||||||||
| Ratings & Reviews | |||||||||
|
Ibrutinib has an average rating of 6.9 out of 10 from a total of 86 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 27% reported a negative effect. |
Imbruvica has an average rating of 6.5 out of 10 from a total of 68 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 31% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Ibrutinib side effects |
View all Imbruvica side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Imbruvica prices |
||||||||
| Dosage Forms | |||||||||
|
N/A |
|
||||||||
| Brand Names | |||||||||
| Imbruvica |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
6 hours |
6 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 502 drugs are known to interact with Ibrutinib:
|
A total of 502 drugs are known to interact with Imbruvica:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
November 13, 2013 |
November 13, 2013 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Kesimpta
Kesimpta (ofatumumab) is used to treat relapsing forms of multiple sclerosis. Includes Kesimpta ...
Jakafi
Jakafi (ruxolitinib) is used to treat myelofibrosis, polycythemia vera, and graft versus host ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.